PL356243A1 - Nowe sposoby wytwarzania i nowa postać krystaliczna leflunomidu - Google Patents
Nowe sposoby wytwarzania i nowa postać krystaliczna leflunomiduInfo
- Publication number
- PL356243A1 PL356243A1 PL00356243A PL35624300A PL356243A1 PL 356243 A1 PL356243 A1 PL 356243A1 PL 00356243 A PL00356243 A PL 00356243A PL 35624300 A PL35624300 A PL 35624300A PL 356243 A1 PL356243 A1 PL 356243A1
- Authority
- PL
- Poland
- Prior art keywords
- leflunomide
- making
- crystalline form
- new crystalline
- novel processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17122899P | 1999-12-16 | 1999-12-16 | |
US17123799P | 1999-12-16 | 1999-12-16 | |
US18264700P | 2000-02-15 | 2000-02-15 | |
US20241600P | 2000-05-08 | 2000-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL356243A1 true PL356243A1 (pl) | 2004-06-28 |
Family
ID=27496942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL00356243A PL356243A1 (pl) | 1999-12-16 | 2000-12-14 | Nowe sposoby wytwarzania i nowa postać krystaliczna leflunomidu |
Country Status (15)
Country | Link |
---|---|
US (3) | US6610718B2 (pl) |
EP (1) | EP1242077A4 (pl) |
JP (1) | JP2003517011A (pl) |
KR (1) | KR20020067545A (pl) |
CN (1) | CN1411373A (pl) |
AU (1) | AU779931B2 (pl) |
CA (1) | CA2397601A1 (pl) |
CZ (1) | CZ20022000A3 (pl) |
HR (2) | HRP20020521A2 (pl) |
HU (1) | HUP0204069A3 (pl) |
IL (1) | IL149792A0 (pl) |
PL (1) | PL356243A1 (pl) |
SK (1) | SK8332002A3 (pl) |
WO (1) | WO2001043742A1 (pl) |
YU (1) | YU45102A (pl) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0987256T3 (da) * | 1997-08-08 | 2002-02-11 | Aventis Pharma Gmbh | Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid |
KR20020067545A (ko) * | 1999-12-16 | 2002-08-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형 |
AU2001228454A1 (en) * | 2000-01-13 | 2001-07-24 | Merck Patent G.M.B.H | Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary |
WO2001060363A1 (en) * | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
US20050158371A1 (en) * | 2002-02-12 | 2005-07-21 | Sumitomo Pharmaceuticals Co., Ltd. | Novel external agent |
WO2006103506A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Sertraline-containing pharmaceutical compositions and a process for preparation thereof |
WO2008040149A1 (en) * | 2006-09-05 | 2008-04-10 | Dexian Dou | Composition and method for treating immune-mediated skin disorders |
CN101143834B (zh) * | 2006-09-15 | 2010-09-08 | 欣凯医药化工中间体(上海)有限公司 | N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法 |
WO2009004374A1 (en) | 2007-06-29 | 2009-01-08 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
NZ585438A (en) | 2007-10-24 | 2012-09-28 | Generics Uk Ltd | Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide |
US8785461B2 (en) | 2008-02-08 | 2014-07-22 | Generics [Uk] Limited | Process for preparing bosentan |
US8975402B2 (en) | 2008-11-03 | 2015-03-10 | Generics [Uk] Limited | HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers |
CN101817797B (zh) * | 2009-02-26 | 2013-04-10 | 江苏亚邦爱普森药业有限公司 | 高纯度3-甲基-n-[4-(三氟甲基)苯基]-4-异噁唑甲酰胺的合成方法 |
TWI665190B (zh) | 2013-11-15 | 2019-07-11 | 阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途 |
US11801232B2 (en) * | 2019-11-27 | 2023-10-31 | Yale University | Targeting of ARID1A-deficient cancers by inhibiting de novo pyrimidine synthesis pathway |
CN112898215B (zh) * | 2021-02-04 | 2022-11-08 | 美罗药业股份有限公司 | 一种来氟米特晶型i的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
US5268382A (en) * | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
GB8619432D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
DK0527736T3 (da) * | 1990-05-18 | 1997-10-20 | Hoechst Ag | Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler. |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
DE19610955A1 (de) * | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
DE19711800A1 (de) * | 1997-03-21 | 1998-09-24 | Hoechst Ag | Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung |
DK0987256T3 (da) * | 1997-08-08 | 2002-02-11 | Aventis Pharma Gmbh | Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid |
EP0933633A1 (en) * | 1997-12-11 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Process for obtaining L-dihydroorotic acid and use thereof |
US7691890B2 (en) * | 1998-03-11 | 2010-04-06 | James W. Williams | Anti-viral uses of leflunomide products |
US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
JP4773010B2 (ja) * | 1999-06-25 | 2011-09-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdhのカーバメート阻害剤のプロドラッグ |
KR20020067545A (ko) * | 1999-12-16 | 2002-08-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형 |
WO2001060363A1 (en) * | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
WO2001072298A1 (en) * | 2000-03-27 | 2001-10-04 | The General Hospital Corporation | Treatments for immune-mediated ear disorders |
AU2001284891A1 (en) * | 2000-08-14 | 2002-02-25 | Teva Pharmaceutical Industries Ltd. | Micronized leflunomide |
ES2321933T3 (es) * | 2000-08-24 | 2009-06-15 | University Of Tennessee Research Foundation | Moduladores selectivos del receptor de androgeno y metodos de uso de los mismos. |
JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
US20040229849A1 (en) * | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
EP1660145A2 (en) * | 2003-08-13 | 2006-05-31 | Medtronic, Inc. | Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices and methods |
EP1684820A2 (en) * | 2003-08-13 | 2006-08-02 | Medtronic, Inc. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
WO2005023201A2 (en) * | 2003-09-09 | 2005-03-17 | Medarex, Inc. | Methods for treating rheumatoid arthritis |
-
2000
- 2000-12-14 KR KR1020027007575A patent/KR20020067545A/ko not_active Application Discontinuation
- 2000-12-14 JP JP2001544880A patent/JP2003517011A/ja active Pending
- 2000-12-14 SK SK833-2002A patent/SK8332002A3/sk unknown
- 2000-12-14 WO PCT/US2000/033866 patent/WO2001043742A1/en not_active Application Discontinuation
- 2000-12-14 AU AU25788/01A patent/AU779931B2/en not_active Ceased
- 2000-12-14 PL PL00356243A patent/PL356243A1/pl not_active Application Discontinuation
- 2000-12-14 CN CN00817283A patent/CN1411373A/zh active Pending
- 2000-12-14 HU HU0204069A patent/HUP0204069A3/hu unknown
- 2000-12-14 IL IL14979200A patent/IL149792A0/xx unknown
- 2000-12-14 YU YU45102A patent/YU45102A/sh unknown
- 2000-12-14 CA CA002397601A patent/CA2397601A1/en not_active Abandoned
- 2000-12-14 US US09/736,727 patent/US6610718B2/en not_active Expired - Fee Related
- 2000-12-14 EP EP00989253A patent/EP1242077A4/en not_active Withdrawn
- 2000-12-14 CZ CZ20022000A patent/CZ20022000A3/cs unknown
-
2002
- 2002-06-14 HR HR20020521A patent/HRP20020521A2/hr not_active Application Discontinuation
-
2003
- 2003-04-08 US US10/410,493 patent/US6806373B2/en not_active Expired - Fee Related
-
2004
- 2004-07-22 US US10/897,778 patent/US20050004191A1/en not_active Abandoned
-
2005
- 2005-02-23 HR HR20050176A patent/HRP20050176A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0204069A2 (hu) | 2003-04-28 |
HRP20050176A2 (en) | 2005-08-31 |
YU45102A (sh) | 2006-01-16 |
AU2578801A (en) | 2001-06-25 |
CN1411373A (zh) | 2003-04-16 |
US20010031878A1 (en) | 2001-10-18 |
JP2003517011A (ja) | 2003-05-20 |
HUP0204069A3 (en) | 2005-01-28 |
EP1242077A4 (en) | 2006-01-04 |
WO2001043742A1 (en) | 2001-06-21 |
HRP20020521A2 (en) | 2004-08-31 |
CA2397601A1 (en) | 2001-06-21 |
US6610718B2 (en) | 2003-08-26 |
KR20020067545A (ko) | 2002-08-22 |
SK8332002A3 (en) | 2003-04-01 |
US6806373B2 (en) | 2004-10-19 |
EP1242077A1 (en) | 2002-09-25 |
US20030203952A1 (en) | 2003-10-30 |
CZ20022000A3 (cs) | 2003-02-12 |
IL149792A0 (en) | 2002-11-10 |
US20050004191A1 (en) | 2005-01-06 |
AU779931B2 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050176A2 (en) | Novel processes for making - and a new crystalline form of-leflunomide | |
IL159332A0 (en) | A knowledge-engineering protocol-suite | |
IL140079A0 (en) | Process for producing bisphennol a | |
HK1044768A1 (zh) | 晶狀1-甲基碳青霉烯化合物 | |
PL352291A1 (en) | Process for making a pipa-polyol | |
SG99351A1 (en) | Process for the manufacture of a crystalline solid | |
GB9901349D0 (en) | A process | |
IL146972A0 (en) | A substantially crystalline form of melagatran | |
AU140192S (en) | A tool | |
ZA982925B (en) | A new process for preparing a compound | |
AU142007S (en) | A cafetiere | |
GB0014546D0 (en) | A novel process | |
GB9916754D0 (en) | A composition | |
SG99292A1 (en) | A method for producing oxide compounds | |
GB2346143B (en) | A compound | |
GB2355450B (en) | A carton for fixings | |
IL132519A0 (en) | A food-serving holder | |
GB2349386B (en) | A compound | |
GB9914111D0 (en) | A tool | |
ZA200203967B (en) | Novel processes for making- and a new crystalline form of leflunomide. | |
GB9906874D0 (en) | A compound | |
SI1196431T1 (sl) | V bistvu kristalna oblika melagatrana | |
AU143085S (en) | A holder | |
AU138548S (en) | A holder | |
AU142145S (en) | A brick |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |